Can we screen high-risk individuals to detect early pancreatic carcinoma?

Research output: Contribution to journalArticle

Abstract

An estimated 10% of individuals with pancreatic cancer have an inherited predisposition to the disease. Germline mutations in BRCA2, p16, STK11, and the cationic trypsinogen gene contribute to inherited forms of pancreatic cancer, but the gene(s) responsible for much of the familial pancreatic cancer burden remains to be identified. The high lifetime risk of pancreatic cancer that exists among at-risk members of families with multiple pancreatic cancers highlights the pressing need for pancreatic cancer early detection strategies. Since curative pancreatic resection is still the only curative treatment for most patients with pancreatic cancer, the early detection of symptomless pancreatic cancer using endoscopic ultrasound or molecular markers may provide the best chance of cure for individuals at high risk of this disease. (C) 2000 Wiley-Liss, Inc.

Original languageEnglish (US)
Pages (from-to)243-248
Number of pages6
JournalJournal of Surgical Oncology
Volume74
Issue number4
DOIs
StatePublished - 2000

Fingerprint

Pancreatic Neoplasms
Trypsinogen
Pancreatic Carcinoma
Germ-Line Mutation
Neoplasm Genes
Genes

Keywords

  • BRCA2
  • DNA methylation
  • Endoscopic ultrasound
  • Familial pancreatic cancer
  • Hereditary pancreatitis
  • p16
  • Screening
  • Telomerase

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

@article{b71c20b4a7c44cbdb029c0354499ef3a,
title = "Can we screen high-risk individuals to detect early pancreatic carcinoma?",
abstract = "An estimated 10{\%} of individuals with pancreatic cancer have an inherited predisposition to the disease. Germline mutations in BRCA2, p16, STK11, and the cationic trypsinogen gene contribute to inherited forms of pancreatic cancer, but the gene(s) responsible for much of the familial pancreatic cancer burden remains to be identified. The high lifetime risk of pancreatic cancer that exists among at-risk members of families with multiple pancreatic cancers highlights the pressing need for pancreatic cancer early detection strategies. Since curative pancreatic resection is still the only curative treatment for most patients with pancreatic cancer, the early detection of symptomless pancreatic cancer using endoscopic ultrasound or molecular markers may provide the best chance of cure for individuals at high risk of this disease. (C) 2000 Wiley-Liss, Inc.",
keywords = "BRCA2, DNA methylation, Endoscopic ultrasound, Familial pancreatic cancer, Hereditary pancreatitis, p16, Screening, Telomerase",
author = "Goggins, {Michael S} and Marcia Canto and Hruban, {Ralph H}",
year = "2000",
doi = "10.1002/1096-9098(200008)74:4<243::AID-JSO1>3.0.CO;2-C",
language = "English (US)",
volume = "74",
pages = "243--248",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Can we screen high-risk individuals to detect early pancreatic carcinoma?

AU - Goggins, Michael S

AU - Canto, Marcia

AU - Hruban, Ralph H

PY - 2000

Y1 - 2000

N2 - An estimated 10% of individuals with pancreatic cancer have an inherited predisposition to the disease. Germline mutations in BRCA2, p16, STK11, and the cationic trypsinogen gene contribute to inherited forms of pancreatic cancer, but the gene(s) responsible for much of the familial pancreatic cancer burden remains to be identified. The high lifetime risk of pancreatic cancer that exists among at-risk members of families with multiple pancreatic cancers highlights the pressing need for pancreatic cancer early detection strategies. Since curative pancreatic resection is still the only curative treatment for most patients with pancreatic cancer, the early detection of symptomless pancreatic cancer using endoscopic ultrasound or molecular markers may provide the best chance of cure for individuals at high risk of this disease. (C) 2000 Wiley-Liss, Inc.

AB - An estimated 10% of individuals with pancreatic cancer have an inherited predisposition to the disease. Germline mutations in BRCA2, p16, STK11, and the cationic trypsinogen gene contribute to inherited forms of pancreatic cancer, but the gene(s) responsible for much of the familial pancreatic cancer burden remains to be identified. The high lifetime risk of pancreatic cancer that exists among at-risk members of families with multiple pancreatic cancers highlights the pressing need for pancreatic cancer early detection strategies. Since curative pancreatic resection is still the only curative treatment for most patients with pancreatic cancer, the early detection of symptomless pancreatic cancer using endoscopic ultrasound or molecular markers may provide the best chance of cure for individuals at high risk of this disease. (C) 2000 Wiley-Liss, Inc.

KW - BRCA2

KW - DNA methylation

KW - Endoscopic ultrasound

KW - Familial pancreatic cancer

KW - Hereditary pancreatitis

KW - p16

KW - Screening

KW - Telomerase

UR - http://www.scopus.com/inward/record.url?scp=0033845951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033845951&partnerID=8YFLogxK

U2 - 10.1002/1096-9098(200008)74:4<243::AID-JSO1>3.0.CO;2-C

DO - 10.1002/1096-9098(200008)74:4<243::AID-JSO1>3.0.CO;2-C

M3 - Article

C2 - 10962454

AN - SCOPUS:0033845951

VL - 74

SP - 243

EP - 248

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 4

ER -